Bank of America
AMLX icon

Bank of America’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bank of America’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Sell
821,841
-508,848
-38% -$7.87M ﹤0.01% 2749
2026
Q1 		$18.5M Sell
1,330,689
-5,321
-0.4% -$74.8K ﹤0.01% 2457
2025
Q4 		$16.1M Buy
1,336,010
+906,494
+211% +$12.3M ﹤0.01% 2473
2025
Q3 		$5.84M Sell
429,516
-22,292
-5% -$210K ﹤0.01% 3842
2025
Q2 		$2.9M Sell
451,808
-342,546
-43% -$1.67M ﹤0.01% 4422
2025
Q1 		$2.81M Sell
794,354
-1,631,909
-67% -$5.81M ﹤0.01% 4370
2024
Q4 		$9.17M Buy
2,426,263
+1,513,748
+166% +$7.12M ﹤0.01% 3039
2024
Q3 		$2.96M Buy
912,515
+434,991
+91% +$978K ﹤0.01% 4223
2024
Q2 		$907K Buy
477,524
+201,568
+73% +$391K ﹤0.01% 4962
2024
Q1 		$784K Buy
275,956
+155,628
+129% +$2.04M ﹤0.01% 5089
2023
Q4 		$1.77M Buy
120,328
+42,142
+54% +$646K ﹤0.01% 4531
2023
Q3 		$1.43M Sell
78,186
-39,025
-33% -$825K ﹤0.01% 4542
2023
Q2 		$2.53M Buy
117,211
+48,887
+72% +$1.32M ﹤0.01% 4007
2023
Q1 		$2M Buy
68,324
+4,958
+8% +$172K ﹤0.01% 4349
2022
Q4 		$2.34M Buy
63,366
+54,479
+613% +$1.93M ﹤0.01% 4103
2022
Q3 		$251K Sell
8,887
-7,683
-46% -$192K ﹤0.01% 5846
2022
Q2 		$319K Buy
16,570
+13,666
+471% +$162K ﹤0.01% 5753
2022
Q1 		$38K Buy
+2,904
New +$65.6K ﹤0.01% 7287

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Bank of America's AMLX Position: Q2 2026 in Review

Bank of America reduced its Amylyx Pharmaceuticals (AMLX) stake by 38% in Q2 2026, selling an estimated $7.87M and leaving 821,841 shares worth $14.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

Bank of America first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. The position peaked at $18.5M in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Bank of America held 821,841 shares of Amylyx Pharmaceuticals worth $14.8M as of Q2 2026.
  • Bank of America sold 508,848 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $7.87M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2749 holding.
  • Bank of America first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Bank of America's Amylyx Pharmaceuticals position peaked at $18.5M in Q1 2026.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.